-
1
-
-
78049485263
-
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
-
1:CAS:528:DC%2BC3cXhtlWhs7fO 21351269 10.1002/ijc.25516
-
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
-
(2010)
Int J Cancer
, vol.127
, Issue.12
, pp. 2893-2917
-
-
Ferlay, J.1
Shin, H.R.2
Bray, F.3
Forman, D.4
Mathers, C.5
Parkin, D.M.6
-
2
-
-
84856472292
-
Management of HCC
-
22300468 10.1016/S0168-8278(12)60009-9
-
de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol. 2012;56(Suppl 1):S75-87.
-
(2012)
J Hepatol
, vol.56
, Issue.SUPPL. 1
-
-
De Lope, C.R.1
Tremosini, S.2
Forner, A.3
Reig, M.4
Bruix, J.5
-
3
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
1:CAS:528:DC%2BD1cXovFWjsL8%3D 18650514 10.1056/NEJMoa0708857
-
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.
-
(2008)
N Engl J Med
, vol.359
, Issue.4
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
Hilgard, P.4
Gane, E.5
Blanc, J.F.6
-
4
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
-
1:CAS:528:DC%2BD1cXhsFChtbnM 19095497 10.1016/S1470-2045(08)70285-7
-
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34.
-
(2009)
Lancet Oncol
, vol.10
, Issue.1
, pp. 25-34
-
-
Cheng, A.L.1
Kang, Y.K.2
Chen, Z.3
Tsao, C.J.4
Qin, S.5
Kim, J.S.6
-
5
-
-
82455162643
-
Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
-
1:CAS:528:DC%2BC3MXhsFCqsLrE 21898496 10.1002/hep.24644
-
Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology. 2011;54(6):2055-63.
-
(2011)
Hepatology
, vol.54
, Issue.6
, pp. 2055-2063
-
-
Iavarone, M.1
Cabibbo, G.2
Piscaglia, F.3
Zavaglia, C.4
Grieco, A.5
Villa, E.6
-
6
-
-
6844255855
-
Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers
-
1:CAS:528:DyaK1cXjsFelsA%3D%3D 9435893 10.1021/jm9704309
-
Umemiya H, Fukasawa H, Ebisawa M, Eyrolles L, Kawachi E, Eisenmann G. Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. J Med Chem. 1997;40(26):4222-34.
-
(1997)
J Med Chem
, vol.40
, Issue.26
, pp. 4222-4234
-
-
Umemiya, H.1
Fukasawa, H.2
Ebisawa, M.3
Eyrolles, L.4
Kawachi, E.5
Eisenmann, G.6
-
7
-
-
0023709173
-
Retinobenzoic acids 1 structure-activity relationships of aromatic amides with retinoidal activity
-
1:CAS:528:DyaL1MXitlCrsQ%3D%3D 3184125 10.1021/jm00119a021
-
Kagechika H, Kawachi E, Hashimoto Y, Himi T, Shudo K. Retinobenzoic acids 1 structure-activity relationships of aromatic amides with retinoidal activity. J Med Chem. 1988;31(11):2182-92.
-
(1988)
J Med Chem
, vol.31
, Issue.11
, pp. 2182-2192
-
-
Kagechika, H.1
Kawachi, E.2
Hashimoto, Y.3
Himi, T.4
Shudo, K.5
-
8
-
-
79957576345
-
Phase i and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333
-
1:CAS:528:DC%2BC3MXpsVCqtr0%3D 21501352 10.1111/j.1872-034X.2011.00800.x
-
Okusaka T, Ueno H, Ikeda M, Morizane C. Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333. Hepatol Res. 2011;41(6):542-52.
-
(2011)
Hepatol Res
, vol.41
, Issue.6
, pp. 542-552
-
-
Okusaka, T.1
Ueno, H.2
Ikeda, M.3
Morizane, C.4
-
9
-
-
62849105898
-
Strategy and mechanism for the prevention of hepatocellular carcinoma: Phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention
-
1:CAS:528:DC%2BD1MXjt1Wrt7k%3D 19068086 10.1111/j.1349-7006.2008.01045.x
-
Shimizu M, Takai K, Moriwaki H. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci. 2009;100(3):369-74.
-
(2009)
Cancer Sci
, vol.100
, Issue.3
, pp. 369-374
-
-
Shimizu, M.1
Takai, K.2
Moriwaki, H.3
-
10
-
-
15044341000
-
Role of constitutively activated and insulin-like growth factor-stimulated ERK1/2 signaling in human hepatoma cell proliferation and apoptosis: Evidence for heterogeneity of tumor cell lines
-
1:CAS:528:DC%2BD2MXivFKktbY%3D 15659801 10.1196/annals.1329.028
-
Alexia C, Lasfer M, Groyer A. Role of constitutively activated and insulin-like growth factor-stimulated ERK1/2 signaling in human hepatoma cell proliferation and apoptosis: evidence for heterogeneity of tumor cell lines. Ann NY Acad Sci. 2004;1030:219-29.
-
(2004)
Ann NY Acad Sci
, vol.1030
, pp. 219-229
-
-
Alexia, C.1
Lasfer, M.2
Groyer, A.3
-
11
-
-
34247193659
-
Inhibition of hepatocellular carcinoma growth by antisense oligonucleotides to type i insulin-like growth factor receptor in vitro and in an orthotopic model
-
1:CAS:528:DC%2BD2sXmtlSmsb8%3D 17441810 10.1111/j.1872-034X.2007.00055.x
-
Lin RX, Wang ZY, Zhang N, Tuo CW, Liang QD, Sun YN, et al. Inhibition of hepatocellular carcinoma growth by antisense oligonucleotides to type I insulin-like growth factor receptor in vitro and in an orthotopic model. Hepatol Res. 2007;37(5):366-75.
-
(2007)
Hepatol Res
, vol.37
, Issue.5
, pp. 366-375
-
-
Lin, R.X.1
Wang, Z.Y.2
Zhang, N.3
Tuo, C.W.4
Liang, Q.D.5
Sun, Y.N.6
-
12
-
-
0036251946
-
A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation
-
1:CAS:528:DC%2BD38XivFKmsL8%3D 11959812
-
Huynh H, Chow PK, Ooi LL, Soo KC. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ. 2002;13(3):115-22.
-
(2002)
Cell Growth Differ
, vol.13
, Issue.3
, pp. 115-122
-
-
Huynh, H.1
Chow, P.K.2
Ooi, L.L.3
Soo, K.C.4
-
13
-
-
0030960368
-
All-trans-retinoic acid increases transforming growth factor-beta2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-alpha-dependent signaling pathway
-
1:CAS:528:DyaK2sXjsFWhsb0%3D 9153223 10.1074/jbc.272.21.13711
-
Han GR, Dohi DF, Lee HY, Rajah R, Walsh GL, Hong WK, et al. All-trans-retinoic acid increases transforming growth factor-beta2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-alpha-dependent signaling pathway. J Biol Chem. 1997;272(21):13711-6.
-
(1997)
J Biol Chem
, vol.272
, Issue.21
, pp. 13711-13716
-
-
Han, G.R.1
Dohi, D.F.2
Lee, H.Y.3
Rajah, R.4
Walsh, G.L.5
Hong, W.K.6
-
14
-
-
0034599989
-
Involvement of insulin-like growth factor binding protein-3 in the retinoic acid receptor-alpha-mediated inhibition of hepatocellular carcinoma cell proliferation
-
1:CAS:528:DC%2BD3cXitFKrt7k%3D 10766424 10.1016/S0304-3835(99)00410-3
-
Murakami K, Matsuura T, Hasumura S, Nagamori S, Yamada Y, Saiki I. Involvement of insulin-like growth factor binding protein-3 in the retinoic acid receptor-alpha-mediated inhibition of hepatocellular carcinoma cell proliferation. Cancer Lett. 2000;151(1):63-70.
-
(2000)
Cancer Lett
, vol.151
, Issue.1
, pp. 63-70
-
-
Murakami, K.1
Matsuura, T.2
Hasumura, S.3
Nagamori, S.4
Yamada, Y.5
Saiki, I.6
-
15
-
-
20844451174
-
Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis
-
1:CAS:528:DC%2BD2MXktl2rtbk%3D 15843826 10.1038/sj.leu.2403754
-
Sanda T, Kuwano T, Nakao S, Iida S, Ishida T, Komatsu H, et al. Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis. Leukemia. 2005;19(6):901-9.
-
(2005)
Leukemia
, vol.19
, Issue.6
, pp. 901-909
-
-
Sanda, T.1
Kuwano, T.2
Nakao, S.3
Iida, S.4
Ishida, T.5
Komatsu, H.6
-
16
-
-
33749261599
-
Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma
-
1:CAS:528:DC%2BD28XhtVGit7rM 16564617 10.1016/j.canlet.2006.01.008
-
Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 2006;242(2):151-67.
-
(2006)
Cancer Lett
, vol.242
, Issue.2
, pp. 151-167
-
-
Pang, R.1
Poon, R.T.2
-
17
-
-
0034307304
-
Activation of retinoic acid receptor alpha is sufficient for full induction of retinoid responses in SK-BR-3 and T47D human breast cancer cells
-
1:CAS:528:DC%2BD3cXns1ehtrg%3D 11034091
-
Schneider SM, Offterdinger M, Huber H, Grunt TW. Activation of retinoic acid receptor alpha is sufficient for full induction of retinoid responses in SK-BR-3 and T47D human breast cancer cells. Cancer Res. 2000;60(19):5479-87.
-
(2000)
Cancer Res
, vol.60
, Issue.19
, pp. 5479-5487
-
-
Schneider, S.M.1
Offterdinger, M.2
Huber, H.3
Grunt, T.W.4
-
18
-
-
4444344411
-
Acyclic retinoid activates retinoic acid receptor beta and induces transcriptional activation of p21(CIP1) in HepG2 human hepatoma cells
-
1:CAS:528:DC%2BD2cXitFCns7s%3D 15026551
-
Suzui M, Shimizu M, Masuda M, Lim JT, Yoshimi N, Weinstein IB. Acyclic retinoid activates retinoic acid receptor beta and induces transcriptional activation of p21(CIP1) in HepG2 human hepatoma cells. Mol Cancer Ther. 2004;3(3):309-16.
-
(2004)
Mol Cancer Ther
, vol.3
, Issue.3
, pp. 309-316
-
-
Suzui, M.1
Shimizu, M.2
Masuda, M.3
Lim, J.T.4
Yoshimi, N.5
Weinstein, I.B.6
-
19
-
-
0035109499
-
Overexpression of retinoic acid receptor beta induces growth arrest and apoptosis in oral cancer cell lines
-
1:CAS:528:DC%2BD3MXitlSms7o%3D 11173543 10.1111/j.1349-7006.2001.tb01046. x
-
Hayashi K, Yokozaki H, Naka K, Yasui W, Lotan R, Tahara E. Overexpression of retinoic acid receptor beta induces growth arrest and apoptosis in oral cancer cell lines. Jpn J Cancer Res. 2001;92(1):42-50.
-
(2001)
Jpn J Cancer Res
, vol.92
, Issue.1
, pp. 42-50
-
-
Hayashi, K.1
Yokozaki, H.2
Naka, K.3
Yasui, W.4
Lotan, R.5
Tahara, E.6
-
20
-
-
0033541438
-
Induction of p21(CIP1/Waf1) and activation of p34(cdc2) involved in retinoic acid-induced apoptosis in human hepatoma Hep3B cells
-
1:CAS:528:DyaK1MXitVWgu7k%3D 10094816 10.1006/excr.1999.4397
-
Hsu SL, Chen MC, Chou YH, Hwang GY, Yin SC. Induction of p21(CIP1/Waf1) and activation of p34(cdc2) involved in retinoic acid-induced apoptosis in human hepatoma Hep3B cells. Exp Cell Res. 1999;248(1):87-96.
-
(1999)
Exp Cell Res
, vol.248
, Issue.1
, pp. 87-96
-
-
Hsu, S.L.1
Chen, M.C.2
Chou, Y.H.3
Hwang, G.Y.4
Yin, S.C.5
-
21
-
-
80051703039
-
All-trans retinoic acid induces cellular senescence via upregulation of p16, p21, and p27
-
1:CAS:528:DC%2BC3MXhtVGmtLrF 21803488 10.1016/j.canlet.2011.07.009
-
Park SH, Lim JS, Jang KL. All-trans retinoic acid induces cellular senescence via upregulation of p16, p21, and p27. Cancer Lett. 2011;310(2):232-9.
-
(2011)
Cancer Lett
, vol.310
, Issue.2
, pp. 232-239
-
-
Park, S.H.1
Lim, J.S.2
Jang, K.L.3
-
22
-
-
49049095498
-
P21 is required for atRA-mediated growth inhibition of MEPM cells, which involves RAR
-
1:CAS:528:DC%2BD1cXps1OhsLs%3D 18425745 10.1002/jcb.21773
-
Yu Z, Li W, Lu Q, Wang L, Zhang X, Han P, et al. p21 is required for atRA-mediated growth inhibition of MEPM cells, which involves RAR. J Cell Biochem. 2008;104(6):2185-92.
-
(2008)
J Cell Biochem
, vol.104
, Issue.6
, pp. 2185-2192
-
-
Yu, Z.1
Li, W.2
Lu, Q.3
Wang, L.4
Zhang, X.5
Han, P.6
-
23
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437 10.1093/jnci/92.3.205
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
-
(2000)
J Natl Cancer Inst
, vol.92
, Issue.3
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
-
24
-
-
33749017926
-
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
-
1:CAS:528:DC%2BD28XhtVGju7jE 10.1200/JCO.2005.01.3441
-
Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J clin oncol: Off J Am Soc Clin Oncol. 2006;24(26):4293-300.
-
(2006)
J Clin Oncol: Off J Am Soc Clin Oncol
, vol.24
, Issue.26
, pp. 4293-4300
-
-
Abou-Alfa, G.K.1
Schwartz, L.2
Ricci, S.3
Amadori, D.4
Santoro, A.5
Figer, A.6
-
25
-
-
33646351795
-
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
-
1:CAS:528:DC%2BD28XkvVajtb8%3D 10.1200/JCO.2005.04.9130
-
Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J clin oncol: Official J Am Soc Clin Oncol. 2006;24(12):1898-903.
-
(2006)
J Clin Oncol: Official J Am Soc Clin Oncol
, vol.24
, Issue.12
, pp. 1898-1903
-
-
Zhu, A.X.1
Blaszkowsky, L.S.2
Ryan, D.P.3
Clark, J.W.4
Muzikansky, A.5
Horgan, K.6
-
26
-
-
32444431720
-
Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level
-
(Oxford, England: 1990)
-
Boige V, Taieb J, Hebbar M, Malka D, Debaere T, Hannoun L, et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. European J cancer (Oxford, England: 1990) 2006;42(4):456-459
-
(2006)
European J Cancer
, vol.42
, Issue.4
, pp. 456-459
-
-
Boige, V.1
Taieb, J.2
Hebbar, M.3
Malka, D.4
Debaere, T.5
Hannoun, L.6
-
27
-
-
27144557565
-
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
-
1:CAS:528:DC%2BD2MXhtFCjtb7O 16234567 10.1093/jnci/dji315
-
Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97(20):1532-8.
-
(2005)
J Natl Cancer Inst
, vol.97
, Issue.20
, pp. 1532-1538
-
-
Yeo, W.1
Mok, T.S.2
Zee, B.3
Leung, T.W.4
Lai, P.B.5
Lau, W.Y.6
-
28
-
-
27244447373
-
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer
-
1:CAS:528:DC%2BD2MXhtFWqsLbJ 10.1200/JCO.2005.14.696
-
Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J clin oncol: Off J Am Soc Clin Oncol. 2005;23(27):6657-63.
-
(2005)
J Clin Oncol: Off J Am Soc Clin Oncol
, vol.23
, Issue.27
, pp. 6657-6663
-
-
Philip, P.A.1
Mahoney, M.R.2
Allmer, C.3
Thomas, J.4
Pitot, H.C.5
Kim, G.6
-
29
-
-
13444303839
-
Thalidomide in the treatment of patients with hepatocellular carcinoma: A phase II trial
-
1:CAS:528:DC%2BD2MXit1Ggsrs%3D 15660400 10.1002/cncr.20821
-
Patt YZ, Hassan MM, Lozano RD, Nooka AK, Schnirer II, Zeldis JB, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 2005;103(4):749-55.
-
(2005)
Cancer
, vol.103
, Issue.4
, pp. 749-755
-
-
Patt, Y.Z.1
Hassan, M.M.2
Lozano, R.D.3
Nooka, A.K.4
Schnirer, I.I.5
Zeldis, J.B.6
-
30
-
-
7744236941
-
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma
-
1:CAS:528:DC%2BD2cXotlKgur8%3D 15248028 10.1007/s00280-004-0837-7
-
Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol. 2004;54(5):385-90.
-
(2004)
Cancer Chemother Pharmacol
, vol.54
, Issue.5
, pp. 385-390
-
-
Lee, J.1
Park, J.O.2
Kim, W.S.3
Park, S.H.4
Park, K.W.5
Choi, M.S.6
-
31
-
-
0037096866
-
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma
-
1:CAS:528:DC%2BD38XltlOqurc%3D 12115351 10.1002/cncr.10607
-
Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2002;94(12):3186-91.
-
(2002)
Cancer
, vol.94
, Issue.12
, pp. 3186-3191
-
-
Fuchs, C.S.1
Clark, J.W.2
Ryan, D.P.3
Kulke, M.H.4
Kim, H.5
Earle, C.C.6
-
32
-
-
0037080414
-
Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy
-
1:CAS:528:DC%2BD38XhtV2qs78%3D 11905412 10.1002/cncr.10236
-
Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer. 2002;94(2):421-7.
-
(2002)
Cancer
, vol.94
, Issue.2
, pp. 421-427
-
-
Leung, T.W.1
Tang, A.M.2
Zee, B.3
Yu, S.C.4
Lai, P.B.5
Lau, W.Y.6
-
33
-
-
36949033865
-
Phase i study of sorafenib in Japanese patients with hepatocellular carcinoma
-
1:CAS:528:DC%2BD1cXnsFWltQ%3D%3D 17953709
-
Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2008;99(1):159-65.
-
(2008)
Cancer Sci
, vol.99
, Issue.1
, pp. 159-165
-
-
Furuse, J.1
Ishii, H.2
Nakachi, K.3
Suzuki, E.4
Shimizu, S.5
Nakajima, K.6
-
34
-
-
59449089100
-
Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: Presence of lung metastasis predicts poor response
-
1:CAS:528:DC%2BD1MXhvFCiurk%3D 19107763 10.1002/cncr.24029
-
Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer. 2009;115(2):428-36.
-
(2009)
Cancer
, vol.115
, Issue.2
, pp. 428-436
-
-
Yau, T.1
Chan, P.2
Ng, K.K.3
Chok, S.H.4
Cheung, T.T.5
Fan, S.T.6
-
35
-
-
3042712893
-
Retinoic acid controls blood vessel formation by modulating endothelial and mural cell interaction via suppression of Tie2 signaling in vascular progenitor cells
-
1:CAS:528:DC%2BD2cXlslWgsLw%3D 15026310 10.1182/blood-2003-09-3293
-
Suzuki Y, Komi Y, Ashino H, Yamashita J, Inoue J, Yoshiki A, et al. Retinoic acid controls blood vessel formation by modulating endothelial and mural cell interaction via suppression of Tie2 signaling in vascular progenitor cells. Blood. 2004;104(1):166-9.
-
(2004)
Blood
, vol.104
, Issue.1
, pp. 166-169
-
-
Suzuki, Y.1
Komi, Y.2
Ashino, H.3
Yamashita, J.4
Inoue, J.5
Yoshiki, A.6
-
36
-
-
17744386930
-
Liver transplantation in patients with portal vein thrombosis
-
1:STN:280:DC%2BD3M3ksVCluw%3D%3D 11172396 10.1053/jlts.2001.21295
-
Manzanet G, Sanjuan F, Orbis P, Lopez R, Moya A, Juan M, et al. Liver transplantation in patients with portal vein thrombosis. Liver Transpl. 2001;7(2):125-31.
-
(2001)
Liver Transpl
, vol.7
, Issue.2
, pp. 125-131
-
-
Manzanet, G.1
Sanjuan, F.2
Orbis, P.3
Lopez, R.4
Moya, A.5
Juan, M.6
-
37
-
-
0031866469
-
Portal vein thrombosis in hepatocellular carcinoma: Age and sex distribution in an autopsy study
-
1:STN:280:DyaK1czosVSjug%3D%3D 9719503 10.1007/s004320050189
-
Pirisi M, Avellini C, Fabris C, Scott C, Bardus P, Soardo G, et al. Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. J Cancer Res Clin Oncol. 1998;124(7):397-400.
-
(1998)
J Cancer Res Clin Oncol
, vol.124
, Issue.7
, pp. 397-400
-
-
Pirisi, M.1
Avellini, C.2
Fabris, C.3
Scott, C.4
Bardus, P.5
Soardo, G.6
-
38
-
-
33646441796
-
Portal vein thrombosis: Prevalence, patient characteristics and lifetime risk: A population study based on 23,796 consecutive autopsies
-
16610067
-
Ogren M, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol. 2006;12(13):2115-9.
-
(2006)
World J Gastroenterol
, vol.12
, Issue.13
, pp. 2115-2119
-
-
Ogren, M.1
Bergqvist, D.2
Björck, M.3
Acosta, S.4
Eriksson, H.5
Sternby, N.H.6
-
39
-
-
45849133795
-
Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma
-
1:CAS:528:DC%2BD1cXotlWqs7w%3D 2496959 18045666 10.1016/j.thromres.2007. 10.009
-
Connolly GC, Chen R, Hyrien O, Mantry P, Bozorgzadeh A, Abt P, et al. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res. 2008;122(3):299-306.
-
(2008)
Thromb Res
, vol.122
, Issue.3
, pp. 299-306
-
-
Connolly, G.C.1
Chen, R.2
Hyrien, O.3
Mantry, P.4
Bozorgzadeh, A.5
Abt, P.6
-
40
-
-
84855876594
-
Tamibarotene-induced low-grade reversible intravascular coagulation in a patient with acute promyelocytic leukemia
-
Ohata K, Yamazaki H, Asakura H, Shimadoi S, Nakao S. Tamibarotene-induced low-grade reversible intravascular coagulation in a patient with acute promyelocytic leukemia. Thromb Res 2012;129(2):213-214
-
(2012)
Thromb Res
, vol.129
, Issue.2
, pp. 213-214
-
-
Ohata, K.1
Yamazaki, H.2
Asakura, H.3
Shimadoi, S.4
Nakao, S.5
-
41
-
-
0030761728
-
Anticoagulant effects of synthetic retinoids mediated via different receptors on human leukemia and umbilical vein endothelial cells
-
1:CAS:528:DyaK2sXltlOku7k%3D 9269772
-
Shibakura M, Koyama T, Saito T, Shudo K, Miyasaka N, Kamiyama R, Hirosawa S. Anticoagulant effects of synthetic retinoids mediated via different receptors on human leukemia and umbilical vein endothelial cells. Blood. 1997;90(4):1545-51.
-
(1997)
Blood
, vol.90
, Issue.4
, pp. 1545-1551
-
-
Shibakura, M.1
Koyama, T.2
Saito, T.3
Shudo, K.4
Miyasaka, N.5
Kamiyama, R.6
Hirosawa, S.7
-
42
-
-
76449097783
-
Expert consensus for the treatment of disseminated intravascular coagulation in Japan
-
1:CAS:528:DC%2BC3cXit1Onsrc%3D 19782389 10.1016/j.thromres.2009.08.017
-
Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010;125(1):6-11.
-
(2010)
Thromb Res
, vol.125
, Issue.1
, pp. 6-11
-
-
Wada, H.1
Asakura, H.2
Okamoto, K.3
Iba, T.4
Uchiyama, T.5
Kawasugi, K.6
-
43
-
-
0033119584
-
Annexin II and bleeding in acute promyelocytic leukemia
-
1:CAS:528:DyaK1MXitlaksrg%3D 10099141 10.1056/NEJM199904013401303
-
Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. New Eng J Med. 1999;340(13):994-1004.
-
(1999)
New Eng J Med
, vol.340
, Issue.13
, pp. 994-1004
-
-
Menell, J.S.1
Cesarman, G.M.2
Jacovina, A.T.3
McLaughlin, M.A.4
Lev, E.A.5
Hajjar, K.A.6
|